Human papillomavirus (HPV) belongs to the papillomavirus family and infects keratinocytes of the skin or mucous membranes. HPV is the most common sexually transmitted infection globally. While many of the more than 170 known types of HPV cause no symptoms, some types can cause warts (HPV6 and HPV11), while others can lead to cancer (HPV16, HPV18, HPV31, HPV45).
Some HPV types lead to cancer of the cervix, vulva, vagina, anus, penis and mouth or throat. Almost all cases of cervical cancer are due to HPV (mostly HPV16 and HPV18). Other high risk HPV types are HPV31 and HPV45.
Some of the early genes, such as E6 and E7, act as oncogenes that promote tumor growth and malignant transformation. For example, E6 protein inactivates the tumor-suppressor protein p53 leading to unregulated cell division and cell growth. Furthermore, HPV can integrate into the host genome which is associated with alterations of genes and gene regulation.
HPV vaccination prevents the most common types of infection and is recommended for preteen males and females aged 9-13. With cervical cancer screening (pap test), cancer precursor cells can be detected early on.
Cellular Immune Response
JPT offers tailored custom peptides, and peptide pools . We provide knowledgeable support, high quality, flexible and innovative formats combined with expert know-how to bring forward your HPV research project. In addition, we offer clinical peptides for specific clinical applications with stringent quality control and at attractive pricing.
- Antigen-specific simulation of T-cells in functional T-cell assays
- Immune monitoring
- Qualification of immunodominant antigens
- Clinical T-cell assay validation
Catalog PepMixes™ for HPV
We offer 21 different antigen-spanning HPV PepMixes from e.g. HPV06, HPV11, HPV16, HPV18, HPV35, HPV45 and HPV58 covering proteins such as E1, E2, E4, E5, E6, E7 and L1.
For an overview please visit our shop.
Tailored HPV PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide. If you would like to order a quality peptide synthesis using regulated processes, choose JPT! > Custom Peptide Synthesis Product Page
Humoral Immune Response Profiling
- Immune monitoring of humoral responses
- Profiling of EBV specific samples or antibodies
- Evaluation of co-infection
- Detection of epitopes and epitope spreading
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
Our tailored Peptide ELISA plates are offered as stand-alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT's peptide microarrays.
JPT's Clinical Peptides product lines GxP and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.
"Incorporation of RG1 Epitope Into HPV16L1-VLP Does Not Compromise L1-Specific Immunity"
Schellenbacher et al, Vaccine (2019)
"Human Papilloma Virus-Specific T Cells can be Generated from Naïve T Cells for use as an Immunotherapeutic Strategy for Immunocompromised Patients"
McCormack et al., Cytotherapy (2018)
"Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and Disease"
Ramos et al., International Jounal of Cancer (2017)
"Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)"
Huber et al., PLoS One (2017)